Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma

Tsuyoshi Fukushima, Makiko Kawaguchi, Kenji Yorita, Hiroyuki Tanaka, Hideo Takeshima, Kazuo Umezawa, and Hiroaki Kataoka

Section of Oncopathology and Regenerative Biology, Department of Pathology (T.F., M.K., K.Y., Hir.T., H.K.); Section of Neurosurgery, Department of Clinical Neuroscience (Hid.T.), Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Kanagawa, Japan (K.U.)

Glioblastoma is the most malignant type of brain tumor. Despite recent advances in therapeutic modalities, the prognosis of glioblastoma remains very poor. Recent studies have indicated that RelA/nuclear factor (NF)-κB is consistently activated in human glioblastoma. In this study, we searched for a new treatment modality for glioblastoma, by examining the effects of dehydroxymethylepoxyquinomicin (DHMEQ), a unique small molecule inhibitor of NF-κB. Addition of DHMEQ to cultured human glioblastoma cells inhibited the nuclear translocation of RelA. It also reduced the growth rate of human glioblastoma cells significantly in 6 cell lines and modestly in 3 among 10 cell lines examined. Then, we performed further analyses using 3 sensitive cell lines (U87, U251, and YKG-1). The growth retardation was accompanied by G2/M arrest in vitro. Increased apoptosis was observed in U87 and YKG-1, but not U251 cells after DHMEQ treatment. Then, we tested the efficacy of DHMEQ in chemoprevention through the use of a nude mouse model. Subcutaneous tumors formed by U87 or U251 cells were reduced by ∼40% in size by intraperitoneal administration of DHMEQ started immediately after implantation of the cells. DHMEQ treatment achieved statistically significant improvements in survival curves of mice intracranially implanted with U87 or U251 cells. Histological analysis revealed increased areas of necrosis, increased numbers of collapsed microvessels, decreased nuclear immunoreactivity of RelA, and decreased immunoreactivity of urokinase-type plasminogen activator in the DHMEQ-treated U87 tumor tissues. These results suggest that the targeting of NF-κB by DHMEQ may serve as a promising treatment modality in glioblastoma.

Keywords: DHMEQ, glioblastoma, NF-κB, RelA.
Angiogenesis factors, such as vascular endothelial growth factor, and proteases, such as urokinase-type plasminogen activator (uPA),\textsuperscript{2,3} Of note, activated RelA/NF-κB is consistently observed in gliomas with a tendency for positive correlation with malignant progression.\textsuperscript{4,5} In vitro studies using cultured glioblastoma cells suggest that RelA/NF-κB is involved in malignant properties of glioblastoma, such as enhanced growth, resistance to apoptosis, invasiveness, and generation of angiogenesis factors.\textsuperscript{3,8} Therefore, RelA/NF-κB may be a promising therapeutic molecular target in glioblastoma.

Dehydroxymethylepoxyquinomicin (DHMEQ) is a recently synthesized small molecule inhibitor of NF-κB.\textsuperscript{9,10} It directly binds to the canonical and noncanonical NF-κB components to inhibit their DNA binding.\textsuperscript{11} It also inhibits nuclear translocation of RelA.\textsuperscript{12} In the initial in vivo study of DHMEQ, it inhibited type-2 collagen-induced arthritis in mice, a model for rheumatoid arthritis in which activation of NF-κB by tumor necrosis factor α (TNFα) plays a pivotal role.\textsuperscript{10} It also inhibited renal inflammation and cancer cachexia.\textsuperscript{10} Subsequently, it has been shown that DHMEQ could suppress the growth of various types of tumor cells.\textsuperscript{10,13–23}

In our search for a new treatment modality for glioblastoma, we examined the effects of DHMEQ on glioblastoma cells, because RelA/NF-κB signaling is known to be activated in glioblastoma cells.\textsuperscript{3,8} To our knowledge, our data demonstrated, for the first time, that DHMEQ could suppress the growth of glioblastoma cells and improved the survival of mice after intracranial transplantation of glioblastoma cells.

Materials and Methods

Cell Lines and Clinical Samples

The human glioblastoma cell lines U87, YKG-1, A172, T98G, U251, KS-1, YH13, U373, NYGM, and MGM-1 were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS). NYGM and MGM-1 were established in our laboratory.\textsuperscript{24,25} U251, YKG-1, T98G, A172, and KS-1 were obtained from the RIKEN cell bank (Tsukuba, Japan). YH-13 was from the Health Science Research Resource Bank (Osaka, Japan). U87 and U373 were from Dainippon Sumitomo Pharma (Osaka, Japan). The experimental protocol for clinical samples was approved by the Human Ethics Review Committees of Miyazaki University. Tissue samples were obtained from surgically resected low-grade gliomas, anaplastic gliomas, and glioblastomas. Normal brain mRNAs were obtained from nonneoplastic portions. Tumors were assessed according to the World Health Organization classification.\textsuperscript{26}

Reagents and Antibodies

DHMEQ was synthesized as described elsewhere,\textsuperscript{9} dissolved in dimethyl sulfoxide (DMSO; 10 mg/mL), and stored at −20°C. Recombinant TNFα was purchased from Boehringer Mannheim Biochemica. Antibodies used were anti-NF-κB p65 (C22B4) rabbit monoclonal (Cell Signaling Technology), anti-lamin A/C rabbit polyclonal (Cell Signaling), anti-cleaved caspase 3 (Asp175) rabbit polyclonal (Cell Signaling), anti-CD31 rabbit polyclonal (AnaSpec), and anti-uPA (R&D Systems) polyclonal antibodies.

Reverse-Transcriptase Polymerase Chain Reaction

Reverse-transcriptase polymerase chain reaction (RT-PCR) was performed as described elsewhere,\textsuperscript{27} using the following primers: RelA, forward 5′-GGGATGGCTTCTATGAGCTGA-3′ and reverse 5′-GGTCTGGATGCGCTGACTGA-3′; uPA, forward 5′-GCCATCCGGGACTATACAGA-3′ and reverse 5′-AGGCCATTCTTTCCCTTGTT-3′; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward 5′-GTGAAGTCGGTGACTCAACG-3′ and reverse, 5′-GGTGAAGACGCGCTGACTC-3′.

Immunoblot Analysis

Cultured cells (60%–70% confluency) were incubated with or without DHMEQ (10 μg/mL) in growth medium for 2.5 h, followed by treatment with TNFα (20 ng/mL) for 30 min in serum-free DMEM, 0.1% bovine serum albumin (BSA). After washing in phosphate-buffered saline (PBS), nuclear proteins were extracted using CelLytec NuCLEAR extraction kit (Sigma). For immunoblot, each extracted protein (4.5 μg) was separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis under reducing conditions, transferred onto Immobilon membrane (Millipore), and processed as described elsewhere.\textsuperscript{27}

Cell Proliferation and Cytotoxicity Assays

Cells were seeded into 96-well plates (10^3 cells/well) and cultured with various concentrations of DHMEQ, and the cell numbers were evaluated using TetraColor ONE assay (SEIKAGAKU) as described elsewhere.\textsuperscript{27} Cytotoxic activity of DHMEQ was evaluated by calculating the concentration required for 50% inhibition of cellular growth (IC50).

Cell Cycle Analysis and Cell Viability Assay

For cell cycle analysis, cells (50% confluency) were starved in serum-free condition for 24 h, followed by incubation in growth medium with or without DHMEQ. At the end of the treatment, the cells were trypsinized to obtain a single-cell suspension, centrifuged, and the pellet was resuspended in PBS, followed by fixation in ice-cold 70% ethanol. The fixed cells were centrifuged at ×450 g for 5 min, washed with PBS, resuspended in Guava Cell Cycle Reagent (Millipore), incubated for 30 min at room temperature in the dark, and analyzed by Guava EasyCyte flow
cytometer (Millipore) according to the manufacturer’s instructions. For cell viability assay, cells were seeded into 6-well plates (1 × 10^5 cells/well) and cultured without or with DHMEQ. The numbers of live cells, apoptotic cells, and dead cells were calculated using Guava ViaCount assay system (Millipore) and Guava EasyCyte flow cytometer with Cytosoft software (Millipore) according to the manufacturer’s instructions.

**Murine Xenograft Models**

All animal procedures were performed in accordance with institutional guidelines, and the protocol was approved by the Animal Care Committee of University of Miyazaki. Six-week-old male athymic nude mice (BALB/cAJc1-nu) with a mean body weight of 20 g were obtained from CLEA Japan. In all experiments, the experimental group was injected intraperitoneally with 10 mg/kg DHMEQ 3 times per week started on the day of tumor injection, and the control group was administered vehicle DMSO solutions. For subcutaneous implantation, glioblastoma cells (5 × 10^6) were implanted subcutaneously in the back of mice. Tumor size was measured twice per week for 4 weeks. Tumor volume was estimated by the formula A × B^2 × 0.5, where A is length and B is width. When mice were sacrificed, blood samples were collected by intracardiac puncture, and hematological biochemistry tests were performed in a clinical laboratory (SRL; Tokyo, Japan). For intracranial transplantation, U87 or U251 cells (1 × 10^5 or 1 × 10^6 cells/10 μL DMEM, respectively) were stereotactically transplanted into the forebrain of mice as described elsewhere.28 The mice were carefully observed every day for 38 days to calculate the Kaplan-Meier survival curves. In another experiment, the brain specimens were prepared after euthanasia of mice 29 days after the transplantation. The brain tissues were fixed in 4% formaldehyde in PBS and sectioned coronally at the point of cellular implantation, followed by embedding in paraffin.

**Immunostaining**

Formalin-fixed paraffin-embedded tissue sections (4 μm) were processed for antigen retrieval (autoclaving in 10 mM citrate buffer [pH. 6.0], for RelA and CD31, and in 1 mM EDTA [pH. 8.0], for cleaved caspase 3). After blocking in 3% BSA and 10% normal goat serum in PBS, the sections were immunostained as described elsewhere.29 For immunocytochemistry, cells were seeded into Lab-Tek chamber slide (Nalge Nunc International) and incubated with or without DHMEQ (10 μg/mL) for 2.5 h. Then, the cells were treated with TNFα (20 ng/mL) for 30 min, fixed with 4% paraformaldehyde in PBS for 15 min, and washed in PBS 3 times. The cells were blocked for 1 h with 5% normal goat serum in PBS with 0.003% Triton X-100 at room temperature, followed by incubation with anti-NF-κB p65 antibody overnight at 4°C. After washing with PBS, the cells were incubated for 1 h at room temperature with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen) in PBS, washed with PBS, counterstained with 4,6-diamino-2-phenylindole (Sigma), and investigated with Axio Imager.A2 (Carl Zeiss MicroImaging).

**Quantification of Microvessel Density, Apoptotic Cells, and Nuclear RelA-Positive Cells In Vivo**

To count microvessel densities, apoptotic cells, nuclear RelA-positive cells, and uPA-positive cells, tissue sections were immunostained with anti-CD31, anti-cleaved caspase 3, anti-NF-κB p65 (RelA), and anti-uPA antibodies, respectively. The stained sections were examined at low power field (×40). Then, 5 areas with the most intense labeling were selected and photographed at ×200 (CD31, cleaved caspase 3, and uPA) or ×400 (RelA) magnification. Two independent investigators (M.K. and H.K. for microvessels and apoptotic cells; K.Y. and Hir.T. for uPA; M.K. and Hir.T. for RelA) counted the positive vessels per cells, and the mean number per field was calculated. For semi-quantification of uPA immunoreactivity, the following score was used: numbers of strongly positive cells × 2 + numbers of weakly positive cells/field.

**Statistical Analysis**

Data were analyzed using the Statview 4.0 program (Brainpower), and the results were expressed as the mean ± standard deviation. Comparison between 2 unpaired groups was done using 2-way repeated-measures analysis of variance or Mann-Whitney U test. Survival of mice was assessed by estimating the Kaplan-Meier survival curves, which were compared by log-rank test. Significance was set at P < .05.

**Results**

**DHMEQ Suppressed Proliferation of Glioblastoma Cells In Vitro**

Enhanced RelA mRNA levels were consistently detected in high-grade gliomas, particularly in glioblastoma, and human glioblastoma cell lines (Fig. 1). We examined the effects of DHMEQ on the proliferation of 10 human glioblastoma cell lines. As shown in Fig. 2A, DHMEQ suppressed the growth of the glioblastoma cell lines. However, the extents of suppression varied among the cell lines (Table 1). Most (9 of 10) cell lines were sensitive to DHMEQ, in which significant suppressive effects were observed in 6 cell lines (YKG-1, U251, U87, MGM-1, NYGM, and U373). YKG-1 showed the highest sensitivity, with an IC50 value of 1.1 μg/mL. As expected, the nuclear translocation of RelA was significantly suppressed by DHMEQ treatment (Fig. 2B). We also examined the effect of DHMEQ on TNFα-induced upregulation of an NF-κB target gene product, uPA. The DHMEQ treatment (6 h) suppressed TNFα-induced upregulation of uPA mRNA.
level in U251 (Fig. 2B). However, the basal level of uPA mRNA was not altered by DHMEQ. Similar effects were observed in YKG-1 (data not shown). On the other hand, U87 did not show TNFα-induced uPA upregulation, and the expression level of uPA in this cell line was not altered by DHMEQ (data not shown).

DHMEQ Induced G2/M Cell Cycle Arrest and Apoptosis in Glioblastoma Cells

Previous studies have indicated that DHMEQ induces G1 arrest17 or G2/M arrest21 of tumor cells, possibly depending on the types of cells used. Therefore, we examined the effects of DHMEQ on cell cycle progression of U87, YKG-1, and U251 cells. After DHMEQ treatment (10 μg/mL), U87 and YKG-1 showed statistically significant increases in the sizes of the G2/M population accompanied by reductions in the G0/G1 fractions, and representative histogram patterns are shown in Fig. 3A. Peak effects were observed 24 h and 12 h after treatment in U87 and YKG-1, respectively (Fig. 3B). In U87 cells, G0/G1 fraction was reduced by 36%, compared with control cells, after 24 h of DHMEQ treatment (data not shown). In YKG-1, G0/G1 fraction was reduced by 33% after 12 h of DHMEQ treatment (Fig. 3A). A tendency of similar cell cycle arrest was observed in U251; however, the effect was modest in this cell line, compared with U87 and YKG-1.

Because NF-κB is known to inhibit apoptosis through the induction of anti-apoptotic proteins and suppression of pro-apoptotic genes, we further examined whether apoptosis also contributed to the observed growth inhibition of glioblastoma cells. The ratios of apoptotic cells were evaluated 3, 12, 24, and 48 h after DHMEQ treatment. Peak effects were observed 48 h and 24 h after the treatment in U87 and YKG-1, respectively (Fig. 4). On the other hand, U251 was resistant to DHMEQ-induced apoptosis (Fig. 4).

DHMEQ Treatment Suppressed the Growth of Glioblastoma Cells In Vivo

To test the effect of DHMEQ on the growth of glioblastoma cells in vivo, we analyzed the nude mouse xenotransplantation model using the highly tumorigenic glioblastoma cell line U87. Subcutaneous injection (5 × 10⁶ cells) of U87 resulted in tumor formation in nude mice. Intraperitoneal injection of DHMEQ (10 mg/kg, 3 times per week) reduced the volume of subcutaneous tumors by 40% (P < .05) (Fig. 5A). Hepatotoxicity was not observed after intraperitoneal DHMEQ injections, as judged by measurements of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin levels in serum samples (Table 2). Similar results were observed in U251 (39% reduction of subcutaneous tumor volume; P < .05) (Fig. 5B). YKG-1 could not form subcutaneous tumor.

DHMEQ Improved the Survival of Mice After Intracranial Implantation of Glioblastoma Cells

Finally, we examined the effect of DHMEQ with use of an intracranial glioblastoma model. In this model, U87 (1 × 10⁵) or U251 (1 × 10⁶) cells were injected into the forebrain and the mice were observed for 38 days or 77 days, respectively. YKG-1 did not show tumorigenic potential in these experimental conditions. As shown in Fig. 6A, intraperitoneal administration of DHMEQ resulted in improved survival, compared with the control group, during the observation period in both U87 and U251 cells. Tumor formation was confirmed in all mice histologically. Next, to compare the size and histology of brain tumors, we performed a similar intracranial implantation experiment and sacrificed the mice 29 days after transplantation of U87. Autopsy revealed that, although the mean tumor masses were comparable between the DHMEQ group and the control group (data not shown), the DHMEQ-treated tumors showed larger necrotic areas (Fig. 6B). Apoptotic cells, indicated by immunoreactivity for cleaved caspase 3, were increased (Fig. 6C), and the difference of labeling index (control, 3.0 ± 0.3; DHMEQ, 7.5 ± 2.6/200 field) was statistically significant (P < .05, Mann-Whitney U test). In addition, although the difference of microvessel densities was not statistically significant (control, 11.4 ± 2.3; DHMEQ, 7.1 ± 2.9/200 field), DHMEQ-treated tumors showed a tendency for increased collapsed microvessels (Fig. 6D). Immunohistochemical study for RelA (Fig. 6E) indicated
that the number of nuclear RelA-positive glioblastoma cells was decreased by DHMEQ treatment ($P < .05$). Moreover, uPA immunoreactivity was also decreased in the DHMEQ-treated U87 cells (Fig. 6F).

**Discussion**

Despite extensive studies on the molecular basis of the pathogenesis and biology of glioblastoma, the
prognosis of glioblastoma remains quite poor, providing a strong incentive to develop additional treatment strategies against this disease.\textsuperscript{1,50,31} In this study, we explored an anti-proliferative effect of DHMEQ on glioblastoma cells in vitro and its possible usefulness in the treatment of glioblastoma in vivo. Growth inhibitory effects of DHMEQ on various kinds of tumors have been reported elsewhere, including prostatic, thyroid, breast, hepato-cellular, urothelial and nasopharyngeal carcinomas,\textsuperscript{13–15,20–22} adult T-cell leukemia,\textsuperscript{16} multiple myeloma,\textsuperscript{17} B-cell lymphoma,\textsuperscript{19} synovial sarcoma,\textsuperscript{18} and uveal melanoma.\textsuperscript{23} Our study indicates that glioblastoma is an additional promising target of the DHMEQ therapy, and the results of our in vivo study provided supportive evidence for possible clinical application of DHMEQ.

Various molecules targeting the NF-κB pathway at different points in the signaling cascade have been developed.\textsuperscript{32} Among them, DHMEQ is unique in that it inhibits the translocation of NF-κB proteins into the nucleus without changing the amount of IκB.\textsuperscript{10,12} The inhibitory effect of DHMEQ is more potent on the NF-κB1(p50)/RelA(p65) heterodimer than on the NF-κB1(p50) homodimer. The amino acid sequence CEGRSAGSl, which appears in RelA, c-Rel, and RelB, is the target.\textsuperscript{33} Although approaches to the targeting of RelA/NF-κB for the treatment of glioblastoma require further analysis, several studies have suggested the possibility that RelA/NF-κB could be a molecular target in glioblastoma therapy. In human gliomas, both the expression levels and the activation status of RelA/NF-κB were correlated with tumor grade.\textsuperscript{4,5} Inhibition of RelA by curcumin or antisense oligonucleotide suppressed cellular migration and invasion in vitro.\textsuperscript{5} Similarly, knockdown of RelA by short hairpin RNA suppressed the growth of glioblastoma cells in vitro.\textsuperscript{7} Furthermore, transfection of anti-RelA/NF-κB intracellular antibody into glioblastoma cells reduced invasive and angiogenic capabilities of the cells in vitro and, more

**Table 1.** Inhibitory effect of DHMEQ on in vitro growth of human glioblastoma cell lines

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>IC50 (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>YKG-1</td>
<td>1.1</td>
</tr>
<tr>
<td>U251</td>
<td>1.4</td>
</tr>
<tr>
<td>U87</td>
<td>1.8</td>
</tr>
<tr>
<td>MGM-1</td>
<td>3.2</td>
</tr>
<tr>
<td>U373</td>
<td>3.4</td>
</tr>
<tr>
<td>NYGM</td>
<td>3.5</td>
</tr>
<tr>
<td>YH13</td>
<td>8.5</td>
</tr>
<tr>
<td>A172</td>
<td>11.3</td>
</tr>
<tr>
<td>KS-1</td>
<td>16.7</td>
</tr>
<tr>
<td>T98G</td>
<td>26.7</td>
</tr>
</tbody>
</table>

![Fig. 3. Effects of DHMEQ on cell cycle and apoptosis in glioblastoma cell lines.](https://academic.oup.com/neuro-oncology/article-abstract/14/1/19/1075846)
importantly, suppressed intracranial growth in vivo. In our current study, targeting RelA/NF-κB with DHMEQ induced growth suppression, G2/M cell cycle arrest, and apoptosis of glioblastoma cells. Therefore, our data confirm the usefulness of targeting RelA/NF-κB in glioblastoma. Moreover, in vivo survival of mice transplanted intracranially with U87 or U251 glioblastoma cells was improved after intraperitoneal administration of DHMEQ, suggesting a clinical application of this small molecule inhibitor of RelA/NF-κB for the treatment of intracranial tumors. However, responses to DHMEQ treatment were not always the same in the glioblastoma cell lines used. For example, the T98G cell line was resistant to DHMEQ-induced growth suppression. The U251 cell line showed significant growth suppression after DHMEQ treatment, but was resistant to DHMEQ-induced apoptosis. It is probable that a dominant intracellular signaling cascade may be different between glioblastoma cell lines, which may result in different responses to DHMEQ treatment. On this point, a recent report reveals that phosphatidylinositol-3-kinase/Akt survival signaling is functioning in T98G, which harbors PTEN (phosphatase and tension homolog located on chromosome 10), whereas NF-κB survival signaling is functioning in
PTEN-deficient U87. The p53 status may also influence the response to DHMEQ, and U251 and T98G have mutant p53 status.

In summary, our study showed that DHMEQ, a small molecule inhibitor of NF-κB, induced growth arrest and apoptosis of glioblastoma cells. Furthermore, in vivo study showed improved survival in the mouse intracranial glioblastoma model, suggesting that the administration of DHMEQ may have clinical use in the chemoprevention of glioblastoma.
glioablastoma growth. On the other hand, our data also suggest that DHMEQ treatment alone is not enough to induce complete remission of the glioablastoma tumor in vivo. Moreover, not all glioablastoma cell lines showed significant DHMEQ sensitivity in vitro. Taken together, we propose that DHMEQ may serve as a promising tool for adjuvant therapy for enhancing the efficacy of conventional treatment modalities in glioblastoma. Further study will be required to explore the usefulness of DHMEQ in the treatment of glioablastoma, particularly in combination with other treatment modalities, such as radiation therapy or chemotherapy using temozolomide.\textsuperscript{33}

Acknowledgment

We thank Ms. Y. Tobayashi for her help in immunostain.

Conflict of interest statement. None declared.

Funding

This work was supported in part by Grant-in-Aid for Scientific Research (20390114 to H.K.) and for Young Scientists (22790384 to T.F.) from the Ministry of Education, Science, Sports and Culture, Japan.

References